Regeneron Pharmaceuticals
PBLS

Regeneron Pharmaceuticals’s Parabilis Medicines Inc PBLS Stock Holding History

Regeneron Pharmaceuticals’s Portfolio PBLS Stock Details PBLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$135M Hold
4,166,666
– – 74.9% 1
2026
Q2 		$114M Buy
+4,166,666
New +$115M 64.35% 1

Other funds holding PBLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Matisse Capital
Matisse Capital Portland, Oregon $256M AUM 15.28% 1-Year Est. Return

Regeneron Pharmaceuticals's PBLS Position: Q3 2026 in Review

Regeneron Pharmaceuticals held its Parabilis Medicines Inc (PBLS) position steady in Q3 2026 at 4,166,666 shares worth $135M. The position accounts for 74.9% of the portfolio, ranked #1.

Regeneron Pharmaceuticals first reported a position in PBLS in Q2 2026 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold PBLS as of Q3 2026.

  • Regeneron Pharmaceuticals held 4,166,666 shares of Parabilis Medicines Inc worth $135M as of Q3 2026.
  • Regeneron Pharmaceuticals left its Parabilis Medicines Inc share count unchanged in Q3 2026.
  • Parabilis Medicines Inc made up 74.9% of Regeneron Pharmaceuticals's portfolio in Q3 2026, its #1 holding.
  • Regeneron Pharmaceuticals first reported a position in Parabilis Medicines Inc in Q2 2026 and has held it in 2 quarters since.
  • 45 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q3 2026.

Based on Regeneron Pharmaceuticals's 13F filing for Q3 2026, filed 5 Nov 2026.